Format
Sort by
Items per page

Send to

Choose Destination

Best matches for oncolytic adenovirus:

Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. Jiang H et al. PLoS One. (2014)

Innate immunity to adenovirus. Hendrickx R et al. Hum Gene Ther. (2014)

Polymeric oncolytic adenovirus for cancer gene therapy. Choi JW et al. J Control Release. (2015)

Search results

Items: 1 to 20 of 1654

1.

Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: focus on fiber chimerism and mosaicism, hexon and pIX.

Stepanenko AA, Chekhonin VP.

Virus Res. 2018 Aug 17. pii: S0168-1702(18)30413-1. doi: 10.1016/j.virusres.2018.08.012. [Epub ahead of print] Review.

PMID:
30125593
2.

Spatial and temporal proteome dynamics of glioma cells during oncolytic adenovirus Delta-24-RGD infection.

González-Morales A, Zabaleta A, Guruceaga E, Alonso MM, García-Moure M, Fernández-Irigoyen J, Santamaría E.

Oncotarget. 2018 Jul 24;9(57):31045-31065. doi: 10.18632/oncotarget.25774. eCollection 2018 Jul 24.

3.

Antibodies against adenovirus fiber and penton base proteins inhibit adenovirus vector-mediated transduction in the liver following systemic administration.

Tomita K, Sakurai F, Iizuka S, Hemmi M, Wakabayashi K, Machitani M, Tachibana M, Katayama K, Kamada H, Mizuguchi H.

Sci Rep. 2018 Aug 17;8(1):12315. doi: 10.1038/s41598-018-30947-z.

4.

Adenovirus armed with VGLL4 selectively kills hepatocellular carcinoma with G2/M phase arrest and apoptosis promotion.

Xie W, Hao J, Zhang K, Fang X, Liu X.

Biochem Biophys Res Commun. 2018 Aug 14. pii: S0006-291X(18)31716-9. doi: 10.1016/j.bbrc.2018.08.036. [Epub ahead of print]

PMID:
30119884
5.

Enhancement of adenovirus infection and adenoviral vector-mediated gene delivery by bromodomain inhibitor JQ1.

Lv B, Li J, Li M, Zhuo Y, Ren K, Li E, Yang G.

Sci Rep. 2018 Aug 1;8(1):11554. doi: 10.1038/s41598-018-28421-x.

6.

The role of JNK phosphorylation as a molecular target to enhance adenovirus replication, oncolysis and cancer therapeutic efficacy.

Wechman SL, Rao XM, Gomez-Gutierrez JG, Zhou HS, McMasters KM.

Cancer Biol Ther. 2018 Aug 1:1-11. doi: 10.1080/15384047.2018.1491503. [Epub ahead of print]

PMID:
30067431
7.

Antitumor virotherapy using syngeneic or allogeneic mesenchymal stem cell carriers induces systemic immune response and intratumoral leukocyte infiltration in mice.

Morales-Molina Á, Gambera S, Cejalvo T, Moreno R, Rodríguez-Milla MÁ, Perisé-Barrios AJ, García-Castro J.

Cancer Immunol Immunother. 2018 Jul 31. doi: 10.1007/s00262-018-2220-2. [Epub ahead of print]

PMID:
30066102
8.

Oncolytic adenovirus, rAd.DCN , inhibits breast tumor growth and lung metastasis in an immune-competent orthotopic xenograft model.

Zhao H, Wang H, Kong F, Xu W, Wang T, Xiao F, Wang L, Huang D, Seth P, Yang Y, Wang H.

Hum Gene Ther. 2018 Jul 21. doi: 10.1089/hum.2018.055. [Epub ahead of print]

PMID:
30032645
9.

Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.

Santos JM, Cervera-Carrascon V, Havunen R, Zafar S, Siurala M, Sorsa S, Anttila M, Kanerva A, Hemminki A.

Mol Ther. 2018 Jul 12. pii: S1525-0016(18)30260-0. doi: 10.1016/j.ymthe.2018.06.001. [Epub ahead of print]

PMID:
30017877
10.

Characterization of a replicating expanded tropism oncolytic reovirus carrying the adenovirus E4orf4 gene.

Kemp V, Dautzenberg IJC, Cramer SJ, Hoeben RC, van den Wollenberg DJM.

Gene Ther. 2018 Jul 16. doi: 10.1038/s41434-018-0032-9. [Epub ahead of print]

PMID:
30013187
11.

Tamoxifen overrides autophagy inhibition in Beclin-1-deficient glioma cells and their resistance to adenovirus-mediated oncolysis via upregulation of PUMA and BAX.

Kaverina NV, Kadagidze ZG, Borovjagin AV, Karseladze AI, Kim CK, Lesniak MS, Miska J, Zhang P, Baryshnikova MA, Xiao T, Ornelles D, Cobbs C, Khramtsov A, Ulasov IV.

Oncogene. 2018 Jul 10. doi: 10.1038/s41388-018-0395-9. [Epub ahead of print]

PMID:
29991800
12.

Remission of spontaneous canine tumors after systemic cellular viroimmunotherapy.

Cejalvo T, Perisé-Barrios AJ, Portillo ID, Laborda E, Rodriguez-Milla MA, Cubillo I, Vázquez F, Sardón D, Ramirez M, Alemany R, Castillo ND, Garcia-Castro J.

Cancer Res. 2018 Jul 10. pii: canres.3754.2017. doi: 10.1158/0008-5472.CAN-17-3754. [Epub ahead of print]

PMID:
29991502
13.

Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy.

Hemminki O, Oksanen M, Taipale K, Liikanen I, Koski A, Joensuu T, Kanerva A, Hemminki A.

Mol Ther Oncolytics. 2018 Apr 22;9:41-50. doi: 10.1016/j.omto.2018.04.003. eCollection 2018 Jun 29.

14.

Advances in oncolytic adenovirus therapy for pancreatic cancer.

Nattress CB, Halldén G.

Cancer Lett. 2018 Jul 5;434:56-69. doi: 10.1016/j.canlet.2018.07.006. [Epub ahead of print]

PMID:
29981812
15.

The Oncolytic Adenovirus XVir-N-31 as a Novel Therapy in Muscle-Invasive Bladder Cancer.

Lichtenegger E, Koll F, Haas H, Mantwill K, Janssen KP, Laschinger M, Gschwend J, Steiger K, Black PC, Moskalev I, Nawroth R, Holm PS.

Hum Gene Ther. 2018 Aug 3. doi: 10.1089/hum.2018.026. [Epub ahead of print]

PMID:
29916265
16.

Loss of Cyclin-Dependent Kinase Inhibitor Alters Oncolytic Adenovirus Replication and Promotes More Efficient Virus Production.

Höti N, Johnson TJ, Chowdhury WH, Rodriguez R.

Cancers (Basel). 2018 Jun 15;10(6). pii: E202. doi: 10.3390/cancers10060202.

17.

Designer Oncolytic Adenovirus: Coming of Age.

Baker AT, Aguirre-Hernández C, Halldén G, Parker AL.

Cancers (Basel). 2018 Jun 14;10(6). pii: E201. doi: 10.3390/cancers10060201. Review.

18.

Oncolytic Viruses for Multiple Myeloma Therapy.

Calton CM, Kelly KR, Anwer F, Carew JS, Nawrocki ST.

Cancers (Basel). 2018 Jun 14;10(6). pii: E198. doi: 10.3390/cancers10060198. Review.

19.

Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus.

Hulin-Curtis SL, Davies JA, Jones R, Hudson E, Hanna L, Chester JD, Parker AL.

Oncotarget. 2018 May 29;9(41):26328-26341. doi: 10.18632/oncotarget.25242. eCollection 2018 May 29.

20.

Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells.

Lei J, Jacobus EJ, Taverner WK, Fisher KD, Hemmi S, West K, Slater L, Lilley F, Brown A, Champion B, Duffy MR, Seymour LW.

J Immunother Cancer. 2018 Jun 13;6(1):55. doi: 10.1186/s40425-018-0350-x.

Supplemental Content

Loading ...
Support Center